-
Angiotensin 1/2 (5-7): Reliable Cell Assays
2026-08-26
This scenario-driven guide explains how Angiotensin 1/2 (5-7), SKU A1049, can support more interpretable cell viability, proliferation, cytotoxicity, and renin-angiotensin system experiments. It covers peptide identity, solubilization, assay controls, dose-response design, cross-domain interpretation, and practical vendor selection.
-
Ceftolozane/Tazobactam: Innovation and Evidence
2026-08-26
This review evaluates ceftolozane/tazobactam as an antipseudomonal cephalosporin/β-lactamase inhibitor combination, emphasizing its PBP-mediated bactericidal action, activity against selected resistant Gram-negative pathogens, pharmacodynamics, and clinical evidence. Its main contribution is the integration of microbiology, resistance mechanisms, pharmacokinetics, animal data, clinical trials, and safety findings into a framework for interpreting a newer β-lactam combination.
-
LRRC8A–Caveolin-1 Axis in PDAC
2026-08-25
The reference study identifies a cholesterol-dependent LRRC8A–Caveolin-1 complex that connects cell-volume regulation with KRAS/EGFR signaling, ribosome biogenesis, and pancreatic ductal adenocarcinoma growth. Its combination of bioinformatics, genetic and pharmacological perturbation, xenografts, and patient-derived organoids provides a mechanistic framework for understanding biosynthetic expansion during S phase.
-
Oncostatin M for Neuroimmune Translation
2026-08-25
A mechanistic and strategic framework for using Recombinant Human Oncostatin M to investigate inflammatory cell states, neuroimmune signaling, and translational hypotheses emerging from CXCL1-CXCR2-driven pancreatic cancer pain research.
-
Vancomycin Hydrochloride: Assay Design
2026-08-24
Vancomycin hydrochloride is more than a Gram-positive antibiotic control: it can define the selectivity boundary of culture-based assays. This article connects its molecular mechanism with selective Moraxella recovery, resistance research, and reproducible workflow design.
-
Breast Cancer Dependence on MCL-1: Apoptotic Function
2026-08-24
The reference study shows that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic control of BAX/BAK, rather than because of a separable non-apoptotic tumor function. Genetic deletion and pharmacological inhibition both impaired tumor growth, supporting apoptosis-centered interpretation of MCL-1 targeting while highlighting the need for BAX/BAK-aware experimental controls.
-
Fluorouracil and SMC Biology in Translational Oncology
2026-08-23
Fluorouracil is more than a conventional cytotoxic benchmark: its thymidylate synthase mechanism creates a tractable model for studying DNA replication stress, while emerging breast cancer data position SMC2 and SMC4 as potential response-associated biomarkers. This article connects established 5-FU pharmacology with a translational strategy for mechanistic sensitivity testing, biomarker validation, and resistance research.
-
Salvianolic acid B in Pulmonary Fibrosis Research
2026-08-22
Salvianolic acid B, also called Dan Shen Suan B, is a polyphenolic natural product studied for LH2-associated collagen cross-linking in pulmonary fibrosis. Peer-reviewed findings link reduced LH2 expression with lower collagen deposition, altered fibrotic remodeling, and inhibition of EMT, FMT, and Wnt/β-catenin signaling in experimental models.
-
Cas9 mRNA–gRNA Editing of LGMN and Metastasis
2026-08-22
The reference study develops a lipid nanoparticle strategy for co-delivering Cas9 mRNA and guide RNA to disrupt LGMN, which encodes the metastasis-associated lysosomal protease legumain. Its key contribution is the integration of optimized in vitro transcription templates, transient CRISPR editing, and functional metastasis assays to connect LGMN disruption with impaired lysosomal/autophagic activity and reduced breast cancer cell migration and invasion.
-
Bestatin, ACE Inhibitors, and Aminopeptidase Selectivity
2026-08-21
Tieku and Hooper’s 1992 study directly compared inhibitor activity across three mammalian cell-surface zinc aminopeptidases, revealing that commonly grouped peptidase inhibitors can have markedly different selectivity profiles. Its findings clarify how bestatin and sulfhydryl ACE inhibitors may produce effects through aminopeptidase W, while also providing a framework for interpreting ACE inhibitor specificity in translational experiments.
-
MDL 28170: Selective Calpain Inhibitor Research
2026-08-20
MDL 28170 is a cell-permeable calpain inhibitor with activity against calpain and cathepsin B. Evidence supports its use in neuroprotection research, ischemia models, apoptosis assays, Schwann cell studies, cardiac injury experiments, and Trypanosoma cruzi infection inhibition, but the compound is not calpain-exclusive.
-
Ellagic acid for CK2 and Senescence Assays
2026-08-20
Ellagic acid connects biochemical casein kinase 2 inhibition with practical cancer biology, oxidative stress, and senescence workflows. Its defined CK2 activity, DMSO-compatible formulation, and compatibility with orthogonal viability and apoptosis readouts make it useful for separating target engagement from nonspecific cytotoxicity.
-
Lipid Nanoparticle Trafficking and Endosomal Escape
2026-08-19
A 2025 International Journal of Pharmaceutics study shows that high endolysosomal activity can increase lipid nanoparticle uptake while trapping particles in peripheral endosomes, reducing delivery to productive perinuclear compartments. The findings reposition intracellular trafficking balance—not uptake alone—as a central determinant of cytosolic release and transgene expression.
-
Diuron: Mechanism, Toxicology, and Research Use
2026-08-19
Diuron, also called 3-(3,4-dichlorophenyl)-1,1-dimethylurea, is a phenylurea photosynthesis inhibitor and herbicide research chemical. A 2025 study linked Diuron exposure to acute kidney injury in experimental models through JAK2/STAT1 signaling, while product specifications define its formulation, solvent compatibility, and storage requirements.
-
EZ Cap™ Cas9 mRNA for Causal Neurobiology
2026-08-18
Discover how Cas9 mRNA can convert Fyn–Stat3 observations into causal gene editing experiments. This guide combines Cap1 and 5-moUTP design with zebrafish neurodegeneration assay strategy, controls, and translational limitations.